Definition and characteristics of bridging therapy (BT) groups. (A) Flowchart providing information on cohorts, analysis workflow, BT concepts, and groups (non-CTX, intermediate CTX, and intensive CTX). (B) Distribution and allocation of patients to BT groups based on exposure to CTX agents during the bridging period. (C) Response before LD depending on the BT group. (D) Kaplan-Meier estimates of the probability of PFS in days since CAR-T infusion depending on the BT group. Median PFS in months and 95% CI are provided above the curves. HRs, 95% CI, and log-rank P value for group comparisons are provided below the curves. The number of patients at risk and the number of events per time point are listed in the table below. (E-G) Box plots showing the ANC (E), platelet count (F), and hemoglobin levels (G) before LD depending on the BT group. The number of measurements per group and the P value of the group comparisons are given above. The framed numbers are the median values. The dashed lines indicate the threshold values for CTC grade 3 and grade 4 events. CR, complete response; CTC, common terminology criteria (for adverse events); HD, high-dose therapy (with subsequent autologous stem cell transplantation); LD, lymphodepletion; MR, minimal response; NA, not available; NE, not evaluable (panel C); NE, not estimable (panel D); PD, progressive disease; PR, partial response; RTX, radiotherapy; SD, stable disease; VGPR, very good partial response.